AlT4™
TLR4 on Alum
The TLR4 agonist is absorbed onto aluminum hydroxide (alum) particles. These alum particles consist of nanometer crystals that assemble into aggregates of several micrometers and provide a stable particulate formulation for the sustained release of adjuvant. In vivo data indicate that TLR4-alum directs the quality of the immune response to a balanced Th1/Th2 response, whereas alum alone induces a strict Th2 response. The product potential of a TLR4-alum formulation is very promising given that the FDA approved GSK’s cervical cancer vaccine Cervarix® containing a very similar MPL-alum adjuvant formulation.
Sold in a vial of 000 mil.
Research-grade only.
Contact us for a Quote for Bulk Orders
$225.00
This information is also available on the Downloadable Product Sheet
Initial Details
Adjuvant Name: AlT4
Chemical Nature: Combination adjuvant-TLR4 agonist on alhydrogel
Primary Receptor: TLR
Secondary Receptor: TLR4
Mechanism of Action: TLR4 and potentially inflammasome
Immune Profile Induced: Mixed Th1/Th2
Drug Master File: No
NIAID Support: Yes
Stability Information: At least 3 months at 2-8 degrees C
Storage Information 2-8 degrees C
In Vivo Use (Preclinical)
Is there an associated publication? No
Disease Area/Pathogen: Virus
Parent Organism: Severe acute respiratory syndrome-related coronavirus
Antigen: Recombinant protein
Immunization Route: IM
Readout: Immunogenicity (serology)
Host Species: Mouse-C57BL/6
Were PK/Toxicology studies conducted? No
Product Grade and Formulation(s)
Product Grade: Research-grade only
Bedside mixing with antigen possible? No
Also used in combination adjuvant-formulation? No
Clinical
Not evaluated in humans yet
AlT4™ is an alum-adsorbed TLR4 agonist. Together they enhance immune responses to antigens and skew to a T<sub>H</sub>1 profile. Each 0.5 mL vial of AlT4™ contains 0.5 mL with 1 mg alhydrogel and 125 μg of TLR4 agonist.
Recently Viewed Items
You haven't viewed at any of the products yet.